

## Investor Briefings & Webinar Notice

**8 July 2024 – Melbourne Australia:** PharmAust Limited (ASX:PAA) (**PharmAust** or the **Company**), a clinical-stage biotechnology company, is pleased to invite interested parties to attend one of its investor information sessions being held in Sydney and Melbourne and webinar.

These sessions will provide an opportunity for existing shareholders and potential investors in PharmAust to learn more about the Company's plans for the Phase 2/3 STRIKE clinical study, and meet the management and executive team.

Sandwiches and refreshments to be provided.

**In person meetings will be hosted by PharmAust Managing Director and CEO, Michael Thurn:**

**Melbourne**

**Monday 15 July**

12:15 for 12:30 presentation

Level 25

367 Collins St

Melbourne VIC 3000

**Sydney**

**Tuesday 16 July**

12:15 for 12:30 presentation

Level 21 Aurora Place

88 Phillip St

Sydney NSW 2000

Registrations of planned attendance is essential for capacity and catering purposes. Please register via the following link:

[In Person Registration Link](#)

**The virtual Webinar will be hosted by PharmAust CEO, Michael Thurn:**

**Tuesday 16 July**

11:00-12:00

Please find below the Webinar Link: [Virtual Webinar Link](#)

This announcement is authorised for release by the Board of Directors of PharmAust Limited.

**For further information, please contact:**

**Dr Michael Thurn**

Managing Director

[investorenquiries@pharmaust.com](mailto:investorenquiries@pharmaust.com)

P +61 (3) 9692 7222

W [www.pharmaust.com](http://www.pharmaust.com)

**Media:**

Catherine Strong

Morrow Sodali

[c.strong@morrrowsodali.com](mailto:c.strong@morrrowsodali.com)

P 0406 759 268

## About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel (MPL) for amyotrophic lateral sclerosis (ALS). ALS is the most common form of motor neurone disease (MND) and affects both upper and lower motor neurons.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic proteins are broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including ALS.

The company recently announced positive top-line results for its Phase 1 MEND study in participants with ALS. PAA is in the planning stages for a registration adaptive Phase 2/3 STRIKE clinical study and anticipates commencing enrolment in H2 CY 2024. This single pivotal study could potentially lead to accelerated approval with the US Food and Drug Administration for monepantel for the treatment of ALS in 2026.

In 2024, the Neurodegenerative Disease Market size is estimated to be worth USD 55.12 billion, with a forecast growth (CAGR) of 7.14% the market size is expected to reach USD 77.82 billion by 2029.<sup>2</sup>

<sup>1</sup> Barceló, M.A., Povedano, M., Vázquez-Costa, J.F. et al. Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia. *Sci Rep* 11, 6207 (2021). <https://doi.org/10.1038/s41598-021-85395-z>

<sup>2</sup> <https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market>

## PharmAust Investor Hub:

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning PharmAust. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

Access the investor hub by scanning the QR code or visiting: <https://investorhub.pharmaust.com/>

